E08A Stock Overview
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Exagen Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.60 |
| 52 Week High | US$8.40 |
| 52 Week Low | US$2.02 |
| Beta | 1.2 |
| 1 Month Change | 13.04% |
| 3 Month Change | 6.56% |
| 1 Year Change | -65.10% |
| 3 Year Change | -86.10% |
| 5 Year Change | n/a |
| Change since IPO | -83.32% |
Recent News & Updates
Recent updates
Shareholder Returns
| E08A | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -1.5% | -2.6% | 1.2% |
| 1Y | -65.1% | 4.5% | -11.7% |
Return vs Industry: E08A underperformed the German Biotechs industry which returned 4.5% over the past year.
Return vs Market: E08A underperformed the German Market which returned -11.7% over the past year.
Price Volatility
| E08A volatility | |
|---|---|
| E08A Average Weekly Movement | 25.0% |
| Biotechs Industry Average Movement | 5.6% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in DE Market | 10.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: E08A is more volatile than 90% of German stocks over the past 3 months, typically moving +/- 25% a week.
Volatility Over Time: E08A's weekly volatility has increased from 16% to 25% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 221 | John Aballi | https://www.exagen.com |
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms.
Exagen Inc. Fundamentals Summary
| E08A fundamental statistics | |
|---|---|
| Market Cap | €42.48m |
| Earnings (TTM) | -€36.74m |
| Revenue (TTM) | €41.62m |
1.0x
P/S Ratio-1.2x
P/E RatioIs E08A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| E08A income statement (TTM) | |
|---|---|
| Revenue | US$45.42m |
| Cost of Revenue | US$22.84m |
| Gross Profit | US$22.57m |
| Other Expenses | US$62.66m |
| Earnings | -US$40.09m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.46 |
| Gross Margin | 49.70% |
| Net Profit Margin | -88.27% |
| Debt/Equity Ratio | 49.8% |
How did E08A perform over the long term?
See historical performance and comparison